sarilumab for COVID-19 - live meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	RCT OBS RCT + OBS	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
REMAP-CAP sarilumab, 2021 NCT02735707		RCT	sarilumab	standard of care	COVID-19 severe or critically	some concern	48/402	conclusif	demonstrated 76 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
ARI-RAF (Della-Torre), 2020		OBS	sarilumab	control	COVID-19 severe or critically	NA	28/28	inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis